{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:18Z","timestamp":1764510378706},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5,1]]},"DOI":"10.2146\/ajhp090328","type":"journal-article","created":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T23:34:12Z","timestamp":1271892852000},"page":"713-723","source":"Crossref","is-referenced-by-count":12,"title":["Bendamustine for the treatment of indolent non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia"],"prefix":"10.1093","volume":"67","author":[{"given":"Anjana","family":"Elefante","sequence":"first","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Lymphoma\/Myeloma Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041509084629000_b1-0670713","unstructured":"United States Food and Drug Administration. Approval letter NDA 22-249. www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2008\/022249s000ltr.pdf (accessed 2010 Mar 4)."},{"key":"2019041509084629000_b2-0670713","unstructured":"United States Food and Drug Administration. Approval letter NDA 22-303. www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2008\/022303s000ltr.pdf (accessed 2010 Mar 4)."},{"key":"2019041509084629000_b3-0670713","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1055\/s-0028-1110470","article-title":"Treatment of multiple myeloma with a new cytostatic agent: gamma-1-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride","volume":"94","author":"Anger","year":"1969","journal-title":"Dtsch Med Wochenschr"},{"key":"2019041509084629000_b4-0670713","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019041509084629000_b5-0670713","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019041509084629000_b6-0670713","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin\u2019s lymphoma: results from a multicenter study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"2019041509084629000_b7-0670713","unstructured":"ClinicalTrials.gov. Bendamustine studies. www.clinicaltrials.gov\/ct2\/results?term=bendamustine (accessed 2010 Feb 1)."},{"key":"2019041509084629000_b8-0670713","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2019041509084629000_b9-0670713","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anticancer Drugs"},{"key":"2019041509084629000_b10-0670713","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.leu.2402651","article-title":"In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia","volume":"16","author":"Schwanen","year":"2002","journal-title":"Leukemia"},{"key":"2019041509084629000_b11-0670713","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00432-002-0331-8","article-title":"Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines","volume":"128","author":"Konstantinov","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019041509084629000_b12-0670713","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin\u2019s lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow","year":"2001","journal-title":"Haematologica"},{"key":"2019041509084629000_b13-0670713","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"key":"2019041509084629000_b14-0670713","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.34873","article-title":"In vitro studies with bendamustine: enhanced activity in combination with rituximab","volume":"29","author":"Rummel","year":"2002","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"2019041509084629000_b15-0670713","first-page":"S54","article-title":"Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin lymphoma","volume":"83","author":"Owen","year":"2008","journal-title":"Pharmacol Ther"},{"key":"2019041509084629000_b16-0670713","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-006-0331-5","article-title":"Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride","volume":"59","author":"Teichert","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019041509084629000_b17-0670713","volume-title":"Treanda (bendamustine hydrochloride) for injection, for intravenous infusion, package insert","year":"2009"},{"key":"2019041509084629000_b18-0670713","unstructured":"American Cancer Society. Cancer facts and figures 2009. www.cancer.org\/downloads\/STT\/500809web.pdf (accessed 2010 Feb 1)."},{"key":"2019041509084629000_b19-0670713","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Hodgkin\u2019s lymphomas. V.1.2009. www.nccn.org\/professionals\/physician_gls\/PDF.nhl.pdf (accessed 18 Mar 2010)."},{"key":"2019041509084629000_b20-0670713","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of ritux-imab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2014 a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019041509084629000_b21-0670713","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin\u2019s lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"2019041509084629000_b22-0670713","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin\u2019s-lymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019041509084629000_b23-0670713","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019041509084629000_b24-0670713","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019041509084629000_b25-0670713","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood.V112.11.2596.2596","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the study group indolent lymphomas (StiL)","volume":"112","author":"Rummel","year":"2008","journal-title":"Blood"},{"key":"2019041509084629000_b26-0670713","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","article-title":"Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy","volume":"132","author":"Lissitchkov","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019041509084629000_b27-0670713","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica"},{"issue":"suppl 4","key":"2019041509084629000_b28-0670713","article-title":"Bendamustine vs fludarabine as second-line treatment for patients with chronic lymphocytic leukemia\u2014first interim results of a randomized study","volume":"19","author":"Niederle","year":"2008","journal-title":"Ann Oncol"},{"key":"2019041509084629000_b29-0670713","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V112.11.330.330","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG)","volume":"112","author":"Fischer","year":"2008","journal-title":"Blood"},{"key":"2019041509084629000_b30-0670713","unstructured":"ClinicalTrials.gov. Fludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab in treating patients with previously untreated B-cell chronic lymphocytic leukemia. www.clinicaltrials.gov\/ct2\/show\/NCT00769522 (accessed 2010 Feb 1)."},{"key":"2019041509084629000_b31-0670713","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Multiple myeloma. V.1.2009. www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf (accessed 18 Mar 2010)."},{"key":"2019041509084629000_b32-0670713","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","article-title":"Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone\u2014a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)","volume":"132","author":"P\u00f6nisch","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019041509084629000_b33-0670713","unstructured":"ClinicalTrials.gov. Bendamustine HCl in relapsed and primary refractory Hodgkin lymphoma. www.clinicaltrials.gov\/ct2\/show\/NCT00705250 (accessed 2010 Feb 1)."},{"key":"2019041509084629000_b34-0670713","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/annonc\/mdm378","article-title":"Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine","volume":"18","author":"Reichmann","year":"2007","journal-title":"Ann Oncol"},{"key":"2019041509084629000_b35-0670713","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s004320050225","article-title":"Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study","volume":"124","author":"Hoffken","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019041509084629000_b36-0670713","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/CAD.0b013e328165d11a","article-title":"Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study","volume":"18","author":"Eichbaum","year":"2007","journal-title":"Anticancer Drugs"},{"key":"2019041509084629000_b37-0670713","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.JTO.0000263714.46449.4c","article-title":"Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer","volume":"2","author":"Koster","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2019041509084629000_b38-0670713","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2006.09.029","article-title":"Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients","volume":"55","author":"Schmittel","year":"2007","journal-title":"Lung Cancer"},{"key":"2019041509084629000_b39-0670713","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/cncr.22846","article-title":"Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)","volume":"110","author":"Hartmann","year":"2007","journal-title":"Cancer"},{"key":"2019041509084629000_b40-0670713","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00001813-200008000-00003","article-title":"Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer","volume":"11","author":"Kollmannsberger","year":"2000","journal-title":"Anticancer Drugs"},{"key":"2019041509084629000_b41-0670713","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.cad.0000175587.31940.19","article-title":"Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC","volume":"16","author":"Von Minckwitz","year":"2005","journal-title":"Anticancer Drugs"},{"key":"2019041509084629000_b42-0670713","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019041509084629000_b43-0670713","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019041509084629000_b44-0670713","first-page":"263","article-title":"Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia","volume":"7","author":"Cheson","year":"2009","journal-title":"Clin Adv Hematol Oncol"},{"key":"2019041509084629000_b45-0670713","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1188\/07.CJON.333-336","article-title":"Toxic epidermal necrolysis","volume":"11","author":"Smith","year":"2007","journal-title":"Clin J Oncol Nurs"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/9\/713\/28424701\/ajhp0713.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T23:29:18Z","timestamp":1711409358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/9\/713\/5130132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,1]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,5,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp090328","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,5,1]]},"published":{"date-parts":[[2010,5,1]]}}}